Key Takeaways
- Revenue missed, partly a timing issue: Revenue fell to ₹83.4 crore, but ₹10.5 crore of goods in transit at cost (roughly ₹5 crore profit) will book later because ocean transit times to the US and Europe have lengthened.
- Margins should improve from here: Cost of materials consumed has already dropped from ~54% to 50-51% as high-value inventory is nearly exhausted, so a return to better margin levels is expected.
- Demand weakness persists through Q3: Management sees Q3 similar to or slightly better than Q2, calls this "the end of what worst we can see," and expects a gradual uptick only from Q4.
- The growth story now rests on a pipeline of new products: With legacy SDA demand crushed by weak global auto and agro markets, management is pointing to 6 agro/pharma intermediate opportunities, 2 polymer products, monoglyme, flame retardants, and electrolyte salts to fill the gap in FY26.
- What to watch next quarter: Whether the first flame retardant order ships, whether electrolyte customer discussions conclude by mid-November, and whether Q3 revenue actually holds the Q2 floor.
Revenue & the Goods-in-Transit Distortion
- Headline revenue understates execution: Executed orders worth roughly ₹93-94 crore were not yet invoiced because transit times to the US and Europe have stretched well beyond the typical 3 weeks due to freight rate issues. Goods in transit rose from ₹7.1 crore to ₹17.53 crore, carrying an estimated ₹5 crore of profit that will book when invoiced.
- Q3 guided flat to slightly better: Management expects Q3 revenue to be "more or less similar to current numbers or maybe a little better," framing Q2 as the trough.
- Full-year revenue revised down: H2 should "potentially reflect or slightly better" than H1, but the year will see a definite downward revision, with the shortfall compensated in the next financial year.
- The miss is not just timing: Even adjusting for goods in transit, revenue is well below the ₹105 crore of the prior quarter, driven by real demand weakness in SDA and delayed commercialization of new products.
Chintan Shah: "So, I think this is the end of what worst we can see is what we are spending at as of now. And now we are absolutely optimistic of gaining from here."
SDA: The Core Business Under Pressure
- Demand has shrunk sharply alongside the decline in global heavy vehicle volumes. The segment is also hurt by a shortage of a key raw material, a by-product of agro-chemical production, because the agro market itself is down, reducing supply of that by-product. Some sales remain in a daily allocation mode.
- Two new petrochemical-side customers have been onboarded to balance the temporary loss of vehicle-application volumes, but vehicle applications are much larger, so the offset is partial.
- Raw material prices have bottomed: Management's "strong belief" is that SDA raw material prices, now at "unrealistically low levels" meeting 20-year records, cannot fall further and can only move up. One key SDA raw material is available cheaper as an import than Tatva's own production cost.
- Euro-7 norms are the structural recovery bet: The segment is already in early commercialization for Euro-7 applications, with a "real strong foothold" expected from mid-to-end 2025 as the norms become applicable from January 2027. Market recovery in commercial vehicle sales is anticipated by early to mid-2025.
Chintan Shah: "So, my strong belief is there is no going down further from here. The only way it can go is move up. So, they are really at unrealistically low levels as of today. Meeting probably records of last 20 years."
New Product Pipeline: The FY26 Growth Engine
- Management is pinning the growth gap on new products: Even if markets remain bad, the products now entering commercialization "will suffice and fulfil the gap in terms of growth" and deliver "decent growth in next fiscal year."
- Flame retardants reached a milestone: One large global MNC customer agreed to a cost-plus pricing mechanism after 2-3 years of discussions and placed the first order for commercial-scale plant approval trials. The order is expected to ship in Q3. At current market prices, producing flame retardants is "absolutely unviable," so the cost-plus deal is critical.
- Monoglyme progressing through scale-up: Trials are running smoothly at a 10 kg catalyst level on new pilot CFC equipment. Equipment for 100 kg catalyst level is ready except for one cooling system expected in early January. The order for final equipment with 1,000 kg catalyst capacity has been placed, with commercialization anticipated by end of calendar year 2025.
- Electrolyte salts nearing commercial inflection: The key customer for energy storage devices is stabilizing its newly established product line, with significant demand growth anticipated from early 2025. Commercial discussions were expected to conclude around Diwali or by mid-November. A second customer, for supercapacitors, is fully qualified but commercialization is not visible, probably not until end of 2025.
- Pharma and agro intermediates stacking up: The first commercial order for a pharma intermediate was successfully executed. A second pharma intermediate is progressing smoothly toward approval, with gradual demand uptick in 2025 and full-scale demand in 2026. A fourth pharma intermediate begins piloting post-Diwali. Two agro intermediates are expected to receive formal approval within Q3 or very early Q4, with strong revenue growth expected. The first commercial order for an agro intermediate will be supplied in Q4.
- Polymer products using electrolysis: Planned trials for one product are successfully completed, meeting stringent end-use quality requirements. Plant trials for a second product begin post-Diwali. Both are expected to commercialize within the next fiscal year.
- Large-volume PTC opportunity: A new application with ultimate end-use in electronics is in piloting after R&D completion, with commercialization anticipated in calendar year 2026.
- Revenue potential is material: Management sees opportunities of ₹200-300 crore in revenue from one or two customers for each new pharma/agro product, a few million dollars each from the electrolyte and supercapacitor customers, and a polymer product targeting 500 to 1,000 tons in a segment that runs to a few thousand tons.
Chintan Shah: "I'm trying to be very conservative in the way we have been talking and things have been evolving in the last few quarters. I'm trying to be very conservative in what I'm saying."
Margins & Costs
- Gross margin tailwind is already in the P&L: Cost of materials consumed has declined from roughly 54% to 50-51% of revenue as consumption of high-value inventory nears its end. Management expects a return to better margin levels from here.
- Electrolyte segment operating leverage: The electrolyte business is currently generating negligible EBITDA, with all costs being absorbed. Any revenue increase from here drops directly to EBITDA because no additional manpower or power is required.
- Flame retardant margins: Will carry "definitely lesser margin than PTC but not too bad," with the benefit that plant overheads get absorbed.
- New distillation plant adds capacity: Work on the new plant is completed, and a new plan to increase production capacity has been approved, with ground-breaking expected by end of November and operations starting November 2025.
Competitive Landscape & Market Context
- Chinese competition hits indirectly: Chinese supply does not compete directly with Tatva Chintan but with Tatva's customers, and this has "deeply reflected" on growth numbers over the last 1.5-2 years.
- All three key end-markets are weak: Automotive, agro-chemical, and polymer segments have all been performing poorly on global markets for the last two years, a macro call management admits it failed to anticipate.
- Bromine sourcing is a potential edge: Tatva has access to bromine in India and can produce and export to Europe without exposure to conflict-zone logistics. Management speculated this may be influencing customer psychology even if spot bromine prices have not moved.
- Capacity expansion already planned: Management expects to run out of capacity within the next 1-1.5 years even after the new capex, and has acquired another plot of land identical in size to the Dahej plant within the Dahej industrial area. Master planning and designing have started.
Chintan Shah: "Logically, I think that could be a matter of concern for the customer, whether it is really not impacting the market, that may be true. But probably that has impacted the psychology, the way the customer thinks."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue trough | Q3 revenue "more or less similar to current numbers or maybe a little better"; this is "the end of what worst we can see" | Q3 FY25 |
| Full-year revenue | Downward revision from prior expectations; H2 to "potentially reflect or slightly better" than H1 | FY25 |
| Revenue recovery | Gradual uptick in demand; new products to fill the growth gap and deliver "decent growth" | From Q4 FY25; FY26 |
| Flame retardants shipment | First commercial-scale plant approval trial order to ship | Q3 FY25 |
| Electrolyte customer discussions | Commercial discussions to conclude | Diwali / mid-November 2024 |
| Monoglyme commercialization | Production installation and commercialization to begin | End of calendar year 2025 |
| SDA recovery | Euro-7 commercialization to show "real strong foothold"; commercial vehicle sales recovery anticipated | Mid-to-end 2025 |
| Electrolyte salts demand | Significant growth from energy storage customer | Early 2025 |
| Electrolyte salts second customer | Onset of commercialization for hybrid vehicle application | Second half of 2025 |
| PASC pharma intermediate | Gradual demand uptick | 2025 |
| PASC pharma intermediate | Full-scale demand | 2026 |
| Large-volume PTC opportunity | Commercialization | Calendar year 2026 |
| New distillation plant | Ground-breaking post-Diwali; operational after 1 year | November 2025 |
| Capacity ceiling | Expect to run out of capacity even after new capex | Within 1-1.5 years |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue from operations | ₹83.5 cr, 14% decline YoY and 21% decline QoQ |
| EBITDA | ₹5.6 cr, 37% drop YoY and 23% decline QoQ |
| EBITDA margin | 6.7%, decreased by 14% YoY due to increase in COGS and other expenses by 12.6% and 1.6% respectively |
| PAT margin | negative 0.8% vs 8% in Q2 FY24 |
| Exports | ₹50.8 cr, contributing 60% of revenue |
| Phase Transfer Catalyst revenue | ₹27.5 cr, 8% decline QoQ, 19% growth YoY |
| Structure Directing Agents revenue | ₹27.1 cr, 23% decline QoQ and 37% drop YoY |
| Pharma & Agro Intermediates and Specialty Chemicals revenue | ₹27.2 cr, 30% decline QoQ and 5% decline YoY |
| Electrolyte Salts revenue | ₹3 cr, 5% decline QoQ, 8% growth YoY |
| Cost of materials consumed | 50–51% of revenue, down from ~54% in prior quarters |
| Goods in transit | ₹17.53 cr, up from ₹7.1 cr in Q1 FY25; additional ₹10.5 cr of executed orders not yet invoiced |
| New distillation plant capex | ₹104–105 cr, ground-breaking post-Diwali, operational by November 2025 |
| SDA market share | ~15–16% globally; market size nearly 7x current volumes, expected to grow ~50% with Euro 7 norms |
| Phase Transfer Catalyst export market share | ~25–30% of volumes |
| New product revenue pipeline (3 pharma + 3 agro) | ₹80–100 cr estimated for FY26, potentially doubling to ₹200–250 cr in FY27 |